First Us Phase Iii Trial For Covid-19 Vaccine Begins

Enlarge / A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts. (credit: Bloomberg/Getty Images) Moderna has given the first doses of its experimental COVID-19 vaccine to participants in what will be a 30,000-person trial, as the United States moved into a new phase of the race to develop a vaccine by the start of next year. The Boston-based biotech said on Monday that it had begun the first Phase III study of a vaccine in the US, a large-scale trial that is usually the last before a new product is submitted for regulatory approval. The company’s shares were up as much as 10.6 percent before paring some of their gains.Read 11 remaining paragraphs | Comments

BING NEWS:
  • Study suggests regular vaccine boosts may help immunocompromised fight COVID-19
    People who have received solid organ transplants and take immunosuppressant medications to prevent rejection are among those most susceptible to the damaging effects of COVID-19, including ...
    07/2/2024 - 7:29 am | View Link
  • Nasal COVID-19 Vaccine Secures Federal Funding for Groundbreaking Clinical Trial
    The trial will evaluate the effectiveness and safety of a new vaccine compared to an FDA-approved mRNA vaccine. University of Georgia-based startup CyanVac LLC has received federal funding to conduct ...
    07/1/2024 - 4:55 pm | View Link
  • NIH-sponsored trial of nasal COVID-19 vaccine opens
    A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now ...
    07/1/2024 - 9:10 am | View Link
  • Moderna developing combined mRNA vaccine for COVID-19, Influenza
    The company claims it provides superior immunity to adults over 50 compared to separate COVID-19 and influenza vaccines.
    06/30/2024 - 1:15 am | View Link
  • Efficacy of Moderna’s Next-Gen COVID-19 Vaccine Confirmed in Trial
    A phase 3 trial evaluating Moderna’s next-generation COVID-19 vaccine, mRNA-1283, met its primary vaccine efficacy endpoint.
    06/28/2024 - 3:06 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News